logo-loader

Follow up study points to 'even bigger opportunity' for Traumakine - Faron Pharma CEO

Published: 09:52 01 Nov 2018 EDT

Dr Markku Jalkanen, CEO of Faron Pharmaceuticals Oy (LON:FARN), tells Proactive London's Andrew Scott they believe unexpectedly high corticosteroid (steroid hormones) use by some patients may have affected the results of its Traumakine INTEREST study.

The Phase III study into acute respiratory distress syndrome (ARDS) yielded a disappointing result in May but further experiments by Faron have opened up the possibility that corticosteroids used in parallel to Traumakine treatment affected Traumakine’s (FP-1201-lyo) efficacy.

Faron Pharmaceuticals outlines groundbreaking work in cancer treatment -...

Dr. Markku Jalkanen, CEO of Faron Pharmaceuticals Limited (AIM:FARN, OTC:FPHAF), delivered a pivotal presentation on the company's groundbreaking work in cancer treatment, focusing on the reprogramming of myeloid cells to combat cancer at the Proactive One2One Investor Conference. Myeloid...

on 02/01/2024